2μg (R: reducing condition, N:non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | FGF R3C,CD333,FGFR-3,FGFR3,JTK4 |
| Accession | P22607-1 |
| Amino Acid Sequence | Glu23-Gly375 with hIgG1 Fc Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 80-95kDa (Reducing) |
| Purity | >95% by SDS-PAGE & > 80% by SEC-HPLC |
| Conjugation | Unconjugated |
| Tag | Human IgG1 Fc |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, PH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | 1.Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb;87(2):110-122. |
Background
FGFR (fibroblast growth factor receptor) is a class of transmembrane proteins that consist of three immunoglobulin-like domains, a transmembrane region, and an intracellular tyrosine kinase domain. They transmit signals through ligand-induced dimerization and autophosphorylation, regulating cell growth and differentiation. Clinically, particularly in the case of FGFR3, gene alterations, abnormal expression (such as upregulation in epithelial tumors), and its activation of the PLCγ signaling pathway are closely associated with tumor development and resistance to endocrine therapies (such as tamoxifen), making it an important therapeutic target for cancer treatment.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of FGF R3 (IIIc) Fc Chimera Protein, Human is more than 80% determined by SEC-HPLC.
